Courtney W. Houchen
YOU?
Author Swipe
View article: Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLD
Hepatocyte MLKL Drives Obesity-Driven Hepatocellular Carcinoma Progression via Mitochondrial Dysfunction Independent of Necroptosis in MASLD Open
Background and Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatocellular carcinoma (HCC), particularly in obesity. Mixed Lineage Kinase Domain Like (MLKL), the effector of proinflammatory ce…
View article: A novel D-peptide modulates DCLK1 gelsolin interactions, reducing PDAC tumor growth
A novel D-peptide modulates DCLK1 gelsolin interactions, reducing PDAC tumor growth Open
What drives inflammation-associated tumorigenesis and progression in pancreatic ductal adenocarcinoma (PDAC)? Doublecortin-like kinase 1 (DCLK1) is a central driver of inflammation-associated tumorigenesis, with elevated expression linked …
View article: Supplementary Table S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Table S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Supplementary Table S1
View article: Supplementary Fig. S6 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S6 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Supplementary Fig. S6. Correlation between TMB and ferroptosis in patients received immunotherapy.
View article: Supplementary Fig. S2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Supplementary Fig. S2. Progression-Free Survival of patients in Van-Allen cohort and Lauss cohort based on ferroptosis level.
View article: Supplementary Fig. S4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Supplementary Fig. S4. The association between tumor ferroptosis level and immunotherapy response in gastric cancer.
View article: Figure 1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Figure 1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Ferroptosis is associated with favorable treatment outcomes in patients receiving immunotherapy. A, The flow chart shows the design of the study. B, OS analysis of patients based on ferroptosis levels in tumor tissue in the I…
View article: Figure 3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Figure 3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Ferroptosis-high tumors showed attenuated immunosenescence and enhanced immune response. A and B, Gene set enrichment analysis to examine ferroptosis enrichment and activation of the immune response in ferroptosis-high and fe…
View article: Supplementary Fig. S3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S3 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Supplementary Fig. S3. Correlation between ferroptosis score and overall survival in cancer patients without receiving immunotherapy.
View article: Figure 2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Figure 2 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Ferroptosis complements liver metastasis and TMB to predict immunotherapy outcomes. A, OS analysis of patients based on the status of liver metastasis and ferroptosis in tumor tissue in the IMvigor210 cohort. B, OS analysis o…
View article: Supplementary Fig. S5 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S5 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Supplementary Fig. S5. Prognosis and TMB of non-small cell lung cancer (NSCLC) are associated with ferroptosis level.
View article: Figure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Figure 4 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Ferroptosis is associated with increased immunogenicity and favorable TIME subtypes. A–D, Compare the expression of ICD biomarker genes in ferroptosis-low and ferroptosis-high tumors in the IMvigor210 cohort. E, Examine the p…
View article: Data from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Data from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Immunotherapy has revolutionized the treatment paradigms of several cancer types, yet only a subset of patients derives durable clinical benefit. Ferroptosis is a programmed cell death facilitated by iron-driven overload of lipid peroxidat…
View article: Supplementary Fig. S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Supplementary Fig. S1 from Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Supplementary Fig. S1. Correlation between ferroptosis level and overall survival of patients in Van-Allen cohort and Hugo cohort.
View article: Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy
Evaluation of Ferroptosis as a Biomarker to Predict Treatment Outcomes of Cancer Immunotherapy Open
Immunotherapy has revolutionized the treatment paradigms of several cancer types, yet only a subset of patients derives durable clinical benefit. Ferroptosis is a programmed cell death facilitated by iron-driven overload of lipid peroxidat…
View article: Balancing Regeneration and Resistance: Targeting DCLK1 to Mitigate Gastrointestinal Radiation Injury and Oncogenesis
Balancing Regeneration and Resistance: Targeting DCLK1 to Mitigate Gastrointestinal Radiation Injury and Oncogenesis Open
Ionizing radiation (IR) poses a dual challenge in medicine; while essential for cancer therapy, it inflicts collateral damage to normal tissues, particularly the gastrointestinal (GI) tract. High-dose IR triggers acute radiation syndrome (…
View article: A Non-canonical Role for Hepatocyte MLKL in Promoting Mitochondrial Dysfunction and Senescence in the Aging Liver
A Non-canonical Role for Hepatocyte MLKL in Promoting Mitochondrial Dysfunction and Senescence in the Aging Liver Open
Liver aging is characterized by chronic inflammation and metabolic dysfunction that contributes to the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Necroptosis, a form of inflammatory cell death, is acti…
View article: A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity
A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity Open
Glioblastoma (GBM) is the most aggressive form of brain cancer, with limited therapeutic options. While microglia contribute to GBM progression, the mechanisms by which they foster a protumorigenic immune environment remain poorly understo…
View article: Retraction Note: Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells
Retraction Note: Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells Open
View article: A Novel D-peptide modulates DCLK1 Gelsolin interactions, reducing PDAC tumor growth
A Novel D-peptide modulates DCLK1 Gelsolin interactions, reducing PDAC tumor growth Open
What drives inflammation-associated tumorigenesis and progression in pancreatic ductal adenocarcinoma (PDAC)? Doublecortin-like kinase 1 (DCLK1) is a central driver of inflammation-associated tumorigenesis, with elevated expression linked …
View article: Correction: Panneerselvam et al. Inflammatory Mediators and Gut Microbial Toxins Drive Colon Tumorigenesis by IL-23 Dependent Mechanism. Cancers 2021, 13, 5159
Correction: Panneerselvam et al. Inflammatory Mediators and Gut Microbial Toxins Drive Colon Tumorigenesis by IL-23 Dependent Mechanism. Cancers 2021, 13, 5159 Open
In the original publication [...]
View article: From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases
From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases Open
Chronic liver diseases, fibrosis, cirrhosis, and HCC are often a consequence of persistent inflammation. However, the transition mechanisms from a normal liver to fibrosis, then cirrhosis, and further to HCC are not well understood. This s…
View article: Surging Liver Transplantation for Nonalcoholic Steatohepatitis from 2000–2022: A National Database Study
Surging Liver Transplantation for Nonalcoholic Steatohepatitis from 2000–2022: A National Database Study Open
Our findings underscore the need for increased resources, particularly for minority, uninsured, or noncitizen individuals requiring LT for NASH. This analysis provides valuable insights into the dynamic landscape of LTs in the context of N…
View article: The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia
The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia Open
View article: Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells
Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells Open
While significant strides have been made in understanding cancer biology, the enhancement in patient survival is limited, underscoring the urgency for innovative strategies. Epigenetic modifications characterized by hereditary shifts in ge…
View article: Blocking of doublecortin-like kinase 1-regulated SARS-CoV-2 replication cycle restores cell signaling network
Blocking of doublecortin-like kinase 1-regulated SARS-CoV-2 replication cycle restores cell signaling network Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to fatal outcomes for subgroups of patients with pre-existing co-morbidities. We previously reported a significant association between high expression levels o…
View article: Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer
Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer Open
View article: Data from DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization
Data from DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization Open
Tumor-associated M2-macrophages are one of the most abundant immunosuppressive cell types in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME). However, the molecular mechanisms responsible for the generation of M2-m…
View article: Supplementrary Figure 2 from DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization
Supplementrary Figure 2 from DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization Open
DCLK1-isoform2 expression increased in PDAC. A) TSVdb webtool were utilized to analyze TCGA-PAAD dataset to identify the expression of different isoforms of DCLK1 in human pancreatic adenocarcinoma. B) DCLK1-isoform2 mRNA is highly express…
View article: Data from DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization
Data from DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization Open
Tumor-associated M2-macrophages are one of the most abundant immunosuppressive cell types in the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME). However, the molecular mechanisms responsible for the generation of M2-m…